Seres Therapeutics Inc (MCRB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Seres Therapeutics Inc (MCRB) has a cash flow conversion efficiency ratio of -0.617x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.36 Million) by net assets ($26.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Seres Therapeutics Inc (MCRB) net asset quality to measure how much of total assets are equity-financed.
Seres Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Seres Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Seres Therapeutics Inc (MCRB) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Seres Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seres Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Airmate Cayman International Co Ltd
TW:1626
|
-0.074x |
|
Promateris SA
RO:PPL
|
N/A |
|
Live Verdure Ltd
AU:LV1
|
-0.448x |
|
LightInTheBox Holding Co Ltd ARD
NYSE:LITB
|
-1.560x |
|
Space Hellas SA
AT:SPACE
|
-0.583x |
|
DSR Corp
KO:155660
|
0.038x |
|
Inovio Pharmaceuticals Inc
NASDAQ:INO
|
2.795x |
|
YATRA ONLINE DL-0001
F:26Y
|
N/A |
Annual Cash Flow Conversion Efficiency for Seres Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Seres Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Seres Therapeutics Inc (MCRB) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.22 Million | $1.12 Million | 0.025x | +100.23% |
| 2024-12-31 | $13.78 Million | $-148.61 Million | -10.781x | -512.09% |
| 2023-12-31 | $-44.86 Million | $-117.35 Million | 2.616x | +112.33% |
| 2022-12-31 | $10.78 Million | $-228.82 Million | -21.220x | -41825.29% |
| 2021-12-31 | $131.51 Million | $6.69 Million | 0.051x | +109.49% |
| 2020-12-31 | $174.75 Million | $-93.61 Million | -0.536x | -133.83% |
| 2019-12-31 | $-48.32 Million | $-76.52 Million | 1.583x | +21.04% |
| 2018-12-31 | $-48.05 Million | $-62.85 Million | 1.308x | +205.14% |
| 2017-12-31 | $60.70 Million | $-75.52 Million | -1.244x | -475.73% |
| 2016-12-31 | $132.63 Million | $43.92 Million | 0.331x | +266.53% |
| 2015-12-31 | $205.39 Million | $-40.84 Million | -0.199x | -151.30% |
| 2014-12-31 | $-26.72 Million | $-10.36 Million | 0.388x | +104.60% |
| 2013-12-31 | $631.00K | $-5.32 Million | -8.433x | -1733.56% |
| 2012-12-31 | $6.36 Million | $-2.92 Million | -0.460x | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more